Ohio clinics achieve EMRAM Stage 7

MetroHealth clinics have achieved the highest level on the HIMSS Electronic Medical Record Adoption Model.

EMRAM tracks progress EMR progress at hospitals and health systems and the 18 MetroHealth clinics in Cleveland have earned the Stage 7 Ambulatory Award.

During the first quarter of 2014, only 4.54 percent of the more than 24,000 U.S. ambulatory clinics in the HIMSS Analytics Database received the Stage 7 Ambulatory Award. 

MetroHealth is a public health system committed to providing healthcare to everyone in Cuyahoga County, Ohio, and improving the health of the community overall. Its 6,000 employees deliver care to everyone at its main campus, just west of downtown Cleveland, and at 16 community health centers. MetroHealth is home to Cuyahoga County’s only Adult Level I Trauma Center and Comprehensive Burn Care Center.

“MetroHealth has a strong culture of leveraging their EHR to improve clinical and business operations, and staff are encouraged to perform at their highest levels of skill, certification and license,” said John Daniels, CNM, FACHE, FHIMSS, CPHIMS, vice president, strategic relations at HIMSS. “MetroHealth has implemented an automated patient notification system to report incidental findings from test results.  For example, if imaging from a trauma case reveals a finding unrelated to the trauma, an automated notification is triggered so that the patient and provider can follow up.  MetroHealth has increased patient notification of incidental findings from 36 percent to 100 percent.  They have also reduced follow-up time for incidental findings by 68 days.”

MetroHealth will be recognized next April at the 2015 Annual HIMSS Conference & Exhibition in Chicago. 

Visit the HIMSS Analytics web site for more information on the Stage 7 award.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.